ClinicalTrials.gg
Not yet recruitingNCT05939986Updated Jul 11, 2023

A Protocol for a Virtual Reality Exposure Therapy for Fear of Flying.

An interventional study of Virtual reality-based exposure treatment with multimodal feedback (VRET-M) and Virtual reality-based exposure treatment with bimodal feedback (VRET-B) in Aerophobia, Virtual Reality Exposure Therapy and Randomized Controlled Trial, sponsored by University of Barcelona. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-11.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by University of Barcelona · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to assess whether adding vibrotactile stimulation to visual and auditory stimulation increases the efficacy of VRET for FoF treatment. Eighty-four participants (18-65 years old) will be assigned to one of three intervention arms, namely the VRET with multimodal feedback (visual, auditory, and vibrotactile; VRET-M), the VRET with bimodal feedback (visual and auditory; VRET-B), or the imagery exposure treatment (IET) without sensory feedback. FoF-related symptoms (primary outcomes) will be measured administering the Fear of Flying Questionnaire-II (QPV-II), the Fear of Flying Scale (FFS), and the Visual Analogic Scale (VAS-A) before and after eight sessions of treatment, and at six- and 12-month follow-ups. Anxiety and the sense of presence experienced during exposure sessions (secondary outcome measures: VAS-A and VAS-P) will also be assessed. It is expected that participants in the VRET-M group will report a further reduction of FoF-related symptomatology after the treatment and at follow-ups compared to participants in the VRET-B and IET groups. Likewise, participants in the VRET-M group are expected to show higher sense of presence levels during exposure sessions in comparison to participants in the VRET-B and IET groups. It is expected that the IET group will report the lowest level of sense of presence and the poorest outcome after treatment and at follow-ups.

Read the detailed description

Participants who meet the inclusion criteria will be invited to participate in the initial treatment session. They will be also required to purchase a flight ticket during the six months after the end of the treatment. Participants will be treated weekly for eight individual sessions. While the first two sessions involve preparation and training, exposure will be conducted between the third and eighth session. The exposure sessions' structure and content will be the same in all conditions. Nevertheless, the VRET-M group will experience vibrotactile cues, while the VRET-B group will not. Furthermore, the IET group will experience its own subjective imagined environment without any external stimulation.

02

Conditions studied

  • Aerophobia
  • Virtual Reality Exposure Therapy
  • Randomized Controlled Trial
  • Anxiety

Browse trials for

Keywords

  • Virtual Reality
  • Fear of Flying
  • Exposure
  • Vibrotactile Cues
  • Anxiety
  • Presence
03

In context

Anxiety Disorders Unverified

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

This study's planned enrollment of 84 is close to the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

University of Barcelona is the lead sponsor of 100 studies on the registry; 30 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who meet the (DSM-5, American Psychiatric Association, APA, 2013) criteria for FoF.

Exclusion criteria

Exclusion Criteria:

  • Individuals with a diagnosis of panic disorder, obsessive-compulsive disorder, or psychotic disorder who have received psychotherapy for their FoF, have been taking prescribed medication for their FoF, or have experienced cardiorespiratory disease or an epilepsy attack will be excluded from the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Multimodal Virtual Reality Exposure Treatment (VRET-M)

    VRET with multimodal feedback including visual, auditory and vibrotactile cues.

    Behavioral: Virtual reality-based exposure treatment with bimodal feedback (VRET-B) · Behavioral: Imagery exposure treatment (IET)

  • Active comparator
    Bimodal Virtual Reality Exposure Treatment (VRET-B)

    VRET with bimodal feedback including visual and auditory cues.

    Behavioral: Virtual reality-based exposure treatment with multimodal feedback (VRET-M) · Behavioral: Imagery exposure treatment (IET)

  • Active comparator
    Imagery Exposure Treatment (IET)

    Imagery exposure treatment without sensory cues.

    Behavioral: Virtual reality-based exposure treatment with multimodal feedback (VRET-M) · Behavioral: Virtual reality-based exposure treatment with bimodal feedback (VRET-B)

Interventions

  • BehavioralVirtual reality-based exposure treatment with multimodal feedback (VRET-M)

    The VRET-M group will experience visual, auditive and vibrotactile cues in the exposure sessions.

  • BehavioralVirtual reality-based exposure treatment with bimodal feedback (VRET-B)

    The VRET-B group will experience visual and auditive cues in the exposure sessions.

  • BehavioralImagery exposure treatment (IET)

    The IET group will experience its own subjective imagined environment without any external stimulation.

06

What researchers measure

Primary outcomes

  1. Fear of Flying (FoF). Administering the Fear of Flying Questionnaire-II (QPV-II) and the Fear of Flying Scale (FFS).

    To what extend I feel fear about flying by plane? The QPV-II is rated from on a 10-point scale (0 = absence of anxiety, 10 = extreme anxiety) with scores ranging from 0 to 300. The FFS is rated on a 5-point scale (0 = not at all, 4 = very much), with scores ranging from 0 to 84.

    Time frame: Before the exposure treatment.

  2. Fear of Flying (FoF). Administering the Fear of Flying Questionnaire-II (QPV-II) and the Fear of Flying Scale (FFS).

    To what extend I feel fear about flying by plane? The QPV-II is rated from on a 10-point scale (0 = absence of anxiety, 10 = extreme anxiety) with scores ranging from 0 to 300. The FFS is rated on a 5-point scale (0 = not at all, 4 = very much), with scores ranging from 0 to 84.

    Time frame: After eight sessions of treatment during eight weeks.

  3. Fear of Flying (FoF). Administering the Fear of Flying Questionnaire-II (QPV-II) and the Fear of Flying Scale (FFS).

    To what extend I feel fear about flying by plane? The QPV-II is rated from on a 10-point scale (0 = absence of anxiety, 10 = extreme anxiety) with scores ranging from 0 to 300. The FFS is rated on a 5-point scale (0 = not at all, 4 = very much), with scores ranging from 0 to 84.

    Time frame: At 6 months follow-up after treatment termination.

  4. Fear of Flying (FoF). Administering the Fear of Flying Questionnaire-II (QPV-II) and the Fear of Flying Scale (FFS).

    To what extend I feel fear about flying by plane? The QPV-II is rated from on a 10-point scale (0 = absence of anxiety, 10 = extreme anxiety) with scores ranging from 0 to 300. The FFS is rated on a 5-point scale (0 = not at all, 4 = very much), with scores ranging from 0 to 84.

    Time frame: At 12 months follow-up after treatment termination.

  5. Anxiety. Administering a Visual Analogue Scale (VAS-A).

    To what extend I feel anxious about flying by plane? measured from 0 (absence of anxiety) to 10 (extreme anxiety).

    Time frame: Before the exposure treatment.

  6. Anxiety. Administering a Visual Analogue Scale (VAS-A).

    To what extend I feel anxious about flying by plane? measured from 0 (absence of anxiety) to 10 (extreme anxiety).

    Time frame: After eight sessions of treatment during eight weeks.

  7. Anxiety. Administering a Visual Analogue Scale (VAS-A).

    To what extend I feel anxious about flying by plane? measured from 0 (absence of anxiety) to 10 (extreme anxiety).

    Time frame: At 6 months follow-up after treatment termination.

  8. Anxiety. Administering a Visual Analogue Scale (VAS-A).

    To what extend I feel anxious about flying by plane? measured from 0 (absence of anxiety) to 10 (extreme anxiety).

    Time frame: At 12 months follow-up after treatment termination.

Secondary outcomes

  1. Anxiety. Administering a Visual Analogue Scale (VAS-A).

    To what extend I feel anxious now? measured from 0 (absence of anxiety) to 10 (extreme anxiety).

    Time frame: Before each exposure session.

  2. Anxiety. Administering a Visual Analogue Scale (VAS-A).

    To what extend I feel anxious now? measured from 0 (absence of anxiety) to 10 (extreme anxiety).

    Time frame: Every 2 minutes during each exposure session of 60 minutes.

  3. Anxiety. Administering a Visual Analogue Scale (VAS-A).

    To what extend I feel anxious now? measured from 0 (absence of anxiety) to 10 (extreme anxiety).

    Time frame: After eight sessions of treatment during eight weeks.

  4. Sense of Presence. Administering the Visual Analogue Scale (VAS-P).

    To what extend I feel present now? measured from 0 (absence of sense of presence) to 10 (extreme sense of presence).

    Time frame: Every 2 minutes during each exposure session of 60 minutes.

07

Study locations

1 site
  • Faculty of Psychology. Universitat de Barcelona
    Barcelona, 08035, Spain
08

References and documents

Publications

  • Van Gerwen LJ, Spinhoven P, Van Dyck R. Behavioral and cognitive group treatment for fear of flying: a randomized controlled trial. J Behav Ther Exp Psychiatry. 2006 Dec;37(4):358-71. doi: 10.1016/j.jbtep.2006.05.002. Epub 2006 Jul 7. PubMed 16828460 ↗
  • Rothbaum BO, Hodges L, Anderson PL, Price L, Smith S. Twelve-month follow-up of virtual reality and standard exposure therapies for the fear of flying. J Consult Clin Psychol. 2002 Apr;70(2):428-32. doi: 10.1037//0022-006x.70.2.428. PubMed 11952201 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2023; primary completion for Oct 2023, 1 month later.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 1 month is below that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jul 11, 2023
StartEst.
Sep 1, 2023
Primary completionEst.
Oct 15, 2023
CompletionEst.
Jan 31, 2024
Last update
Jul 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05939986
Responsible party
José María Ribé Viñes (Principal Investigator, University of Barcelona) — Principal investigator
First posted
Jul 11, 2023
Start date
Sep 1, 2023 (estimated)
Primary completion
Oct 15, 2023 (estimated)
Completion
Jan 31, 2024 (estimated)
Last update
Jul 11, 2023

Study contacts

José María MR Ribé Viñes, MD
Contact
jmribev@gmail.com
676022376 ext. +34
Marta MS Ferrer Garcia, PhD
Contact
martaferrerg@ub.edu
933125114 ext. +34
José MR Gutiérrez Maldonado, PhD
study director · Senior PhD Supervisor

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion